Crystalline forms of a prolyl hydroxylase inhibitor
The present disclosure relates to crystalline solid forms of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof.
1. A method of treating anemia associated with chronic kidney disease, comprising administering to a patient in need thereof, a therapeutically effective amount of crystalline [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid (Compound A Form A) characterized by an X-ray powder diffractogram comprising the following peaks: 8.5, 16.2, and 27.4 °2θ±0.2 °2θ.
2. The method of claim 1 , wherein the diffractogram further comprises peaks at 12.8, 21.6, and 22.9 °2θ±0.2 °2θ.
3. The method of claim 1 , wherein the diffractogram is substantially as shown in FIG. 1 .
4. The method of claim 1 , wherein the Compound A Form A is characterized by a differential scanning calorimetry (DSC) curve that comprises an endotherm at about 223° C.
5. The method of claim 4 , wherein the DSC curve is substantially as shown in FIG. 2 .
6. The method of claim 1 , wherein Compound A Form A is administered in a pharmaceutical composition which further comprises a pharmaceutically acceptable excipient.